ArticleTranslational psychiatry2020
Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients.
Article in Translational psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Neurostructural, Neurofunctional, and Clinical Features of Chronic, Untreated Schizophrenia: A Narrative Review.Schizophrenia bulletin · 2025Pooled it
- Longitudinal brain structural changes during clozapine treatment: associations with neuroreceptor architecture and clinical response.medRxiv : the preprint server for health sciences · 2026Article
- Deciphering the Heterogeneity of Schizophrenia: A Multimodal and Multivariate Neuroimaging Framework for Unveiling Brain-Symptom Relationships and Underlying Subtypes.Schizophrenia bulletin · 2026Article
- Neural substrates of treatment-resistant schizophrenia and the response to clozapine: A structural MRI study in a clinical setting.PloS one · 2026Article
- Altered cortical gyrification as a marker of treatment resistance in patients with first-episode psychosis.Translational psychiatry · 2025Article
- Intractable prefrontal and limbic white matter network disruption in adolescents with drug-naïve nonsuicidal self-injury.BMC psychiatry · 2025Article
- Thinning of the temporal and insular cortex is associated with negative symptoms and impaired attention in Chinese chronic schizophrenia patients with deficit syndrome.BMC psychiatry · 2025Article
- Drug-Induced Cognitive Impairment.Drug safety · 2025Review
- Molecular and micro-architectural mapping of gray matter alterations in psychosis.Molecular psychiatry · 2025Article
- Subgroups of cognitive impairments in schizophrenia characterized by executive function and their morphological features: a latent profile analysis study.BMC medicine · 2025Article
- Decreased low-frequency amplitude of the right caudate nucleus in patients with chronic schizophrenia treated with risperidone combined with clozapine.Frontiers in psychiatry · 2025Article
- MRI-based insights into brain structural and functional alterations in schizophrenia treated with risperidone.Frontiers in psychiatry · 2025Review
- Cognitive subgroups of affective and non-affective psychosis show differences in medication and cortico-subcortical brain networks.Scientific reports · 2024Article
- Novel Insights into Psychosis and Antipsychotic Interventions: From Managing Symptoms to Improving Outcomes.International journal of molecular sciences · 2024Review
- The effect of dopamine replacement therapy on cortical structure in Parkinson's disease.CNS neuroscience & therapeutics · 2024Article
- Machine learning in small sample neuroimaging studies: Novel measures for schizophrenia analysis.Human brain mapping · 2024Article
- Electrophysiological Markers Predicting Antipsychotic Treatment Response in Patients with Schizophrenia: A Retrospective Study.Neuropsychiatric disease and treatment · 2024Article
- Transcriptomic and neuroimaging data integration enhances machine learning classification of schizophrenia.Psychoradiology · 2024Article
- Impaired erythropoietin-producing hepatocellular B receptors signaling in the prefrontal cortex and hippocampus following maternal immune activation in male rats.Genes, brain, and behavior · 2023Article
- Basal-Forebrain Cholinergic Nuclei Alterations are Associated With Medication and Cognitive Deficits Across the Schizophrenia Spectrum.Schizophrenia bulletin · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Though gray matter deficits have been consistently revealed in chronic treated schizophrenia, it is still not clear whether there are different brain alterations between chronic never treated and treated patients. To explore the different patterns of gray matter alterations among chronic never treated patients and those treated with monotherapy, we recruited 35 never-treated chronic schizophrenia patients with illness durations ranging from 5 to 48 years, 20 illness duration-matched risperidone monotherapy and 20 clozapine monotherapy patients, and 55 healthy controls. GM (surface area, cortical thickness, and cortical volume) measures were extracted and compared using ANCOVA across the four groups followed by post hoc tests. Relative to controls, both treated and never-treated chronic schizophrenia patients showed reduced GM mainly involving the bilateral medial and rostral middle frontal, left banks superior temporal sulcus, left fusiform, and left pericalcarine cortex and increased in the left cuneus. Compared with the untreated patient group, the two treated groups showed reductions mainly in the bilateral prefrontal, temporal, and left inferior parietal lobules. The clozapine monotherapy patients demonstrated more severe decreases in the bilateral prefrontal cortex and left cuneus and less severe decreases in the left ventral temporal lobe than risperidone monotherapy patients. These findings provide new insights into the long-term effects of antipsychotic treatment on gray matter alterations in schizophrenia patients. Furthermore, the characteristic findings of reductions in the inferior parietal lobule might be specific for long-term antipsychotic treatment, which could be a possible target for medication development in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.